| |
|
 |
|
|
|
|
a |
filler |
| |
|
| |
Lab Location: #5-12
email:
fbard@imcb.a-star.edu.sg
tel:65869585
|
|
| a |
a |
a |
|
|
|
| a |
a |
a |
| |
|
| |
Dimitri Moreau, Pankaj Kumar, Shyi Chyi Wang, Alexandre Chaumet, Shin Yi Chew, Hélène Chevalley, Frédéric Bard.
Genome-Wide RNAi Screens Identify Genes Required for Ricin and PE Intoxications.
Dev Cell (2011) vol. 21 (2) pp. 231-44.
Gill D, Clausen H, Bard F
Location, Location, Location: New insights into O-GalNAc protein glycosylation.
Trends in Cell Biology. 2010 Dec 8; Epub ahead of print.
Chia NY, Chan YS, Feng B, Lu X, Orlov YL, Moreau D, Kumar P,Yang L, Jiang J, Lau MS, Huss M,
Soh BS, Kraus P, Li P, Lufkin T, Lim B, Clarke N, Bard F*, Huck-Hui Ng* (* corresponding authors)
A genome-wide RNAi screen reveals determinants of human ES cell identity.
Nature 2010 Nov 11;468(7321):316-20.
Gill DJ, Chia J, Senewiratne J, Bard F.
Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes.
J Cell Biol. 2010 May 31;189(5):843-58.
R Bard F, Malhotra V
Transit from the Trans-Golgi Network to the plasma membrane.
Annu Rev Cell Dev Biol. 2006;22:439-55
Bard F, Casano L, Mallabiabarrena A, Wallace E, Saito K, Kitayama H, Guizzinti G, Hu Y, DasGupta R, Perrimon N, Malhotra V. Functional genomics reveals new genes involved in protein secretion and Golgi organization.Nature. 2006 Feb 2;439(7076):604-7
Bard F, Mazelin L, Pechoux-Longin C, Malhotra V, Jurdic P.
Src regulates Golgi structure and KDEL receptor-dependent retrograde transport to the endoplasmic reticulum. J Biol Chem. 2003 Nov 21;278(47):46601-6.
Destaing O, Saltel F, Geminard JC, Jurdic P, Bard F.
Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. Mol Biol Cell. 2003 Feb;14(2):407-16.
|
|
| a |
a |
a |
|
| a |
a |
a |
| |
|
| |
Emilie A. Bard-Chapeau, Justin Jeyakani, Chung H. Kok, Julius Muller,
Belinda Q. Chua, Jayantha Gunaratne, Arsen Batagov, Piroon Jenjaroenpun, Vladimir A. Kuznetsov, Chia-Lin Wei, Richard J. D'Andrea, Guillaume Bourque, Nancy A. Jenkins and Neal G. Copeland.
Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.
Published online before print January 19, 2012, doi: 10.1073/pnas.1119229109
Bard-Chapeau EA, Li S, Ding J, Zhang SS, Princen F, Zhu HH, Fang DD, Han T, Bailly-Maitre B, Poli V, Wang H, Feng GS.
PTPN11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis.
Cancer Cell, 2011 May;19(5):629-39
Princen F, Bard E, Sheikh F, Zhang SS, Wang J, Zago WM, Wu D, Diaz Trelles R, Bailly-Maitre B, Kahn CR, Chen Y, Reed JC, Tong GG, Mercola M, Chen J, Feng GS.
Deletion of Shp2 Tyrosine Phosphatase in Muscle Leads to Dilated Cardiomyopathy, Insulin Resistance and Premature Death.
Mol Cell Biol. .2009 Jan;29(2):378-88.
Bailly-Maitre B, Bard-Chapeau E, Luciano F, Droin N, Bruey JM, Faustin B, Kress C, Zapata JM, Reed JC.
Mice lacking bi-1 gene show accelerated liver regeneration. Cancer Res. 2007 Feb 15;67(4):1442-50.
Ke Y, Lesperance J, Zhang EE, Bard-Chapeau EA, Oshima RG, Muller WJ, Feng GS.
Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation.
J Biol Chem. 2006 Nov 10;281(45):34374-80
Bard-Chapeau, E., Yuan, J., Droin, N., Long, S., Zhang, E.E., Nguyen, T., and Feng, GS.
Concerted Functions of Gab1 and Shp2 in Liver Regeneration and Hepatoprotection.
Mol Cell Biol, 2006 Jun;26(12):4664-74
Bard-Chapeau, E., Hevener, A., Long, S., Zhang, E.E., Olefsky, JM., and Feng, GS. Deletion of Gab1 in the Liver Leads to Enhanced Glucose tolerance and Improved Hepatic Insulin Action.
Nature Medicine, 2005 Jun;11(6):567-71
Zhang, E.E., Chapeau, E., Hagihara, K. and Feng, GS.
Neuronal Shp2 Tyrosine Phosphatase Controls Energy Balance and Metabolism.
Proc Natl Acad Sci U S A. 2004 Nov;101(45):16064-9.
|
|
| a |
a |
a |
|
|
 |
|
Frederic BARD |
|
|
Frederic Bard did his graduate work at Yale University, USA and at the Ecole Normale Superieure of Lyon, France where he obtained his PhD. He elucidated the dynamics of the sealing zone, a unique actin cytoskeleton structure in osteoclasts required for bone resorption. During his postdoctoral work at the University of California San Diego (2001-2006), he identified a collection of new genes essential for general protein secretion, the TANGO genes.
Assistant PI: Emilie BARD-CHAPEAU
|
| |
|
|
|
|
Regulation of Membrane Traffic |
| |
|
The human cell is organized into multiple intracellular compartments. Compartmentalization controls many aspects of cellular physiology and has increased in complexity throughout evolution. Most cellular compartments are bound, like the whole cell itself, by lipid-based membranes and exchange material through the trafficking of membrane-bound structures.
We wish to understand how this membrane traffic is regulated to mediate various cellular functions. One of the technologies we use to address these questions is RNA interference screening at the genomic scale, which allows us to identify novel key players in these processes.
We focus on two questions:
1) How trafficking regulation at the Golgi complex affects glycosylation in health and disease
2) How intracellular trafficking is exploited by pathogens and toxins
|
The Golgi apparatus
 |
| |
|
Legend: Human Hela cells stained for the nucleus (blue), the microtubules network (red) and the Golgi apparatus (green). |
|
| |
|
|
|
|
Emilie BARD-CHAPEAU |
| |
|
|
|
|
Assistant
Principal Investigator: Emilie BARD-CHAPEAU
email: ebard@imcb.a-star.edu.sg
Tel:65869872
Liver Cancer Genetics
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide, and hepatitis B is its main risk factor. Genomic alterations are thought to combine with the viral infection to drive cells into a cancerous state. However, the identification of genes that drive this process has been challenging because of the high amount of background mutations. To resolve this issue, we created genetically engineered mouse models that mimic human chronic HBV disease and carry a Sleeping Beauty transposon system for cancer gene discovery. Forward genetic screens led to the identification of functional HCC-driving genes and pathways that constitute potential therapeutic targets. To verify the clinical relevance of these target genes, we now assess their differential expression in human tumor samples. We then plan to optimize genetic therapies using our HBV/HCC mouse model. We will explore the effects of gene targeting on HCC growth, angiogenesis and metabolism with our best candidate genes. Novel metabolic pathways are targeted at the genomic level in liver tumors. We currently verify and quantify the disruption of these pathways using metabolic profiling and live metabolic imaging. These studies will potentially provide novel opportunities for diagnostic or therapy for liver cancer.
|
| |
|
|
|
|
|
